Ómar Vesga

Use of Preclinical Data for Selection of a Phase II/III Dose for Evernimicin and Identification of a Preclinical MIC Breakpoint

George L. Drusano, Sandra L. Preston, C. Hardalo et al. · Antimicrobial Agents and Chemotherapy · 2001 · 242 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseases

Andrés F. Zuluaga, Beatríz Salazar, Carlos A. Rodríguez et al. · BMC Infectious Diseases · 2006 · 202 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacology +12

Staphylococcus aureus Small Colony Variants Are Induced by the Endothelial Cell Intracellular Milieu

Ómar Vesga, Michael Groeschel, M.F. Otten et al. · The Journal of Infectious Diseases · 1996 · 180 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +10

In Vivo Pharmacodynamic Activities of Two Glycylcyclines (GAR-936 and WAY 152,288) against Various Gram-Positive and Gram-Negative Bacteria

M L van Ogtrop, David R. Andes, T. Stamstad et al. · Antimicrobial Agents and Chemotherapy · 2000 · 178 citations

Medicine, Pharmacokinetics, Pharmacology +17

Variant subpopulations of Staphylococcus aureus as cause of persistent and recurrent infections.

Richard A. Proctor, James M Balwit, Ómar Vesga · PubMed · 1994 · 138 citations

Life Sciences, Infectious Diseases, Microbiology +13